{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT02919306",
      "OrgStudyIdInfo": {
        "OrgStudyId": "CR108161"
      },
      "SecondaryIdInfoList": {
        "SecondaryIdInfo": [
          {
            "SecondaryId": "VAC89220HTX1001",
            "SecondaryIdType": "Other Identifier",
            "SecondaryIdDomain": "Janssen Vaccines & Prevention B.V."
          }
        ]
      },
      "Organization": {
        "OrgFullName": "Janssen Vaccines & Prevention B.V.",
        "OrgClass": "INDUSTRY"
      },
      "BriefTitle": "Safety and Efficacy Study of Vaccine Schedule With Ad26.Mos.HIV and MVA-Mosaic in Human Immunodeficiency Virus (HIV)-Infected Adults",
      "OfficialTitle": "A Combined Phase 1/2a, Exploratory Study of a Therapeutic Vaccine Using an Adenovirus Type 26 Vector Prime and Modified Vaccinia Ankara Boost Combination With Mosaic Inserts in HIV-1 Infected Adults Who Initiated Antiretroviral Treatment During Acute HIV Infection"
    },
    "StatusModule": {
      "StatusVerifiedDate": "September 2019",
      "OverallStatus": "Completed",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "October 2016",
        "StartDateType": "Actual"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "September 2018",
        "PrimaryCompletionDateType": "Actual"
      },
      "CompletionDateStruct": {
        "CompletionDate": "September 2018",
        "CompletionDateType": "Actual"
      },
      "StudyFirstSubmitDate": "September 1, 2016",
      "StudyFirstSubmitQCDate": "September 27, 2016",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "September 29, 2016",
        "StudyFirstPostDateType": "Estimate"
      },
      "DispFirstSubmitDate": "September 17, 2019",
      "DispFirstSubmitQCDate": "September 17, 2019",
      "DispFirstPostDateStruct": {
        "DispFirstPostDate": "September 20, 2019",
        "DispFirstPostDateType": "Actual"
      },
      "LastUpdateSubmitDate": "September 17, 2019",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "September 20, 2019",
        "LastUpdatePostDateType": "Actual"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Sponsor"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Janssen Vaccines & Prevention B.V.",
        "LeadSponsorClass": "INDUSTRY"
      }
    },
    "OversightModule": {
      "OversightHasDMC": "Yes",
      "IsFDARegulatedDevice": "No"
    },
    "DescriptionModule": {
      "BriefSummary": "The purpose of the study is to assess: 1 safety and tolerability of adenovirus serotype 26 (Ad26) prime and Modified Vaccinia Ankara (MVA) boost versus placebo in participants on suppressive antiretroviral therapy (ART) that was initiated during acute Human Immunodeficiency Virus (HIV) infection; 2) Measure the frequency and duration of sustained viremic control after receiving Ad26 prime/MVA boost or placebo, defined as greater than 24 weeks with plasma HIV ribonucleic acid (RNA) lesser than (<)50 copies/ml after antiretroviral (ARV) analytical treatment interruption (ATI)."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Human Immunodeficiency Virus"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 1",
          "Phase 2"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "Randomized",
        "DesignInterventionModel": "Parallel Assignment",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "Double",
          "DesignWhoMaskedList": {
            "DesignWhoMasked": [
              "Participant",
              "Investigator"
            ]
          }
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "27",
        "EnrollmentType": "Actual"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "Ad26.Mos.HIV Vaccine or MVA mosaic Vaccine",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "Participants will receive adenovirus serotype 26-Mosaic -Human Immunodeficiency Virus (Ad26.Mos.HIV) 0.5 milliliter (mL) injection intramuscularly (containing 5 * 10^10 viral particles [vp]) at Weeks 0 and 12 followed by modified Vaccinia Ankara-Mosaic (MVA mosaic) 0.5 mL injection (containing 10^8 Plaque-forming unit [pfu]) at Week 24 and 48.",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: Ad26.Mos.HIV",
                "Biological: MVA-Mosaic"
              ]
            }
          },
          {
            "ArmGroupLabel": "Placebo",
            "ArmGroupType": "Placebo Comparator",
            "ArmGroupDescription": "0.5 mL Sodium Chloride Injection United States Pharmacopeia (USP) 0.9% will be administered by intramuscular (IM) injection.",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Drug: Placebo"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Biological",
            "InterventionName": "Ad26.Mos.HIV",
            "InterventionDescription": "Recombinant replication-deficient Ad26 vectored vaccine and consists of 3 Ad26 vectors, one containing a mosaic insert of envelope (Env) sequence, and 2 vectors containing mosaic inserts of Gag and Pol sequences (Ad26.Mos.1.Env + Ad26.Mos1.Gag-Pol + Ad26.Mos2.Gag-Pol). Total dose is 5*10^10 viral particle per 0.5 milliliter (mL) injection administered intramuscularly.",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Ad26.Mos.HIV Vaccine or MVA mosaic Vaccine"
              ]
            }
          },
          {
            "InterventionType": "Biological",
            "InterventionName": "MVA-Mosaic",
            "InterventionDescription": "Recombinant live attenuated MVA virus-vectored vaccine that has been genetically engineered to express 2 mosaic Gag, Pol, and Env sequences (Mosaic 1 and Mosaic 2). Total dose is 10^8 plaque-forming unit per 0.5 mL injection administered intramuscularly.",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Ad26.Mos.HIV Vaccine or MVA mosaic Vaccine"
              ]
            }
          },
          {
            "InterventionType": "Drug",
            "InterventionName": "Placebo",
            "InterventionDescription": "Participants will receive placebo intramuscularly Weeks 0, 12, 24 and 48.",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Placebo"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "Number of Participants With Vaccine Related - Grade 3 or Greater Reactogenicity and Adverse Events as a Measure of Safety and Tolerability",
            "PrimaryOutcomeTimeFrame": "Day 1 through Week 96"
          },
          {
            "PrimaryOutcomeMeasure": "Number of Participants With Human Immunodeficiency Virus (HIV) Ribonucleic Acid (RNA) less than (<)50 copies per milliliter (copies/ml) at 24 Weeks After Antiretroviral (ARV) Analytical Treatment Interruption (ATI)",
            "PrimaryOutcomeTimeFrame": "Week 60"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "Cell-Associated HIV RNA in Total Cluster of Differentiation (CD)4+ Thymus (T) Cells",
            "SecondaryOutcomeDescription": "Assessment of residual HIV replication and viral reservoir in total CD4+ T cells as measured by quantitative real-time polymerase chain reaction (PCR).",
            "SecondaryOutcomeTimeFrame": "Week 96"
          },
          {
            "SecondaryOutcomeMeasure": "Cell-Associated HIV RNA in the Memory CD4 Subsets",
            "SecondaryOutcomeDescription": "Assessment of residual HIV replication and viral reservoir in memory CD4+T cells as measured by quantitative real-time PCR.",
            "SecondaryOutcomeTimeFrame": "Week 96"
          },
          {
            "SecondaryOutcomeMeasure": "Cell-Associated Human Immunodeficiency Virus Deoxyribonucleic Acid (HIV DNA) (total, integrated and 2 Long Terminal Repeats [LTR] Circles) in Total CD4+ T Cells",
            "SecondaryOutcomeDescription": "Assessment of the viral reservoir in total CD4+ T cells as measured by total and integrated HIV DNA and by 2-LTR circles.",
            "SecondaryOutcomeTimeFrame": "Week 96"
          },
          {
            "SecondaryOutcomeMeasure": "Cell-Associated HIV DNA (Total, Integrated and 2 LTR Circles) in the Memory CD4 Subsets",
            "SecondaryOutcomeDescription": "Assessment of the viral reservoir in memory CD4+ T cells as measured by total and integrated HIV DNA and by 2-LTR circles.",
            "SecondaryOutcomeTimeFrame": "Week 96"
          },
          {
            "SecondaryOutcomeMeasure": "Quantification of Latent HIV in Total CD4+ T Cells Using a Viral Outgrowth Assay",
            "SecondaryOutcomeDescription": "Quantitative viral outgrowth assay (QVOA) performed on participants undergoing leukapheresis and only if plasma HIV-1 RNA viral load less than (<)50 copies/mL to evaluate the viral outgrowth.",
            "SecondaryOutcomeTimeFrame": "Week 96"
          },
          {
            "SecondaryOutcomeMeasure": "Quantification of Latent HIV in Memory CD4+ T Cells Using a Viral Outgrowth Assay",
            "SecondaryOutcomeTimeFrame": "Week 96"
          },
          {
            "SecondaryOutcomeMeasure": "Quantification of the Size of the Inducible Viral Reservoir in Total CD4+ T Cells",
            "SecondaryOutcomeDescription": "Measurement of the magnitude of the inducible viral reservoir will be done using the tat/rev induced limiting dilution assay (TILDA) using total CD4+ T cells.",
            "SecondaryOutcomeTimeFrame": "Week 96"
          },
          {
            "SecondaryOutcomeMeasure": "Quantification of the Size of the Inducible Viral Reservoir in Memory CD4+ T Cells",
            "SecondaryOutcomeDescription": "Measurement of the magnitude of the inducible viral reservoir will be done using the tat/rev induced limiting dilution assay (TILDA) using memory CD4+ T cells.",
            "SecondaryOutcomeTimeFrame": "Week 96"
          },
          {
            "SecondaryOutcomeMeasure": "Single Copy HIV RNA in Samples With HIV RNA <50 copies per milliliter (copies/ml) pre and post Antiretroviral (ARV) Analytical Treatment Interruption (ATI)",
            "SecondaryOutcomeTimeFrame": "Week 96"
          },
          {
            "SecondaryOutcomeMeasure": "Frequency of Epitope Recognition by Enzyme-Linked Immunospot (ELISPOT)",
            "SecondaryOutcomeDescription": "Assays of peptide pool sets covering the Gag, Env or Pol will be evaluated by standard enzyme linked immunospot assay (ELISPOT) with mapping of positive pools to determine the number of positive epitopes.",
            "SecondaryOutcomeTimeFrame": "Week 96"
          },
          {
            "SecondaryOutcomeMeasure": "Magnitude of Epitope Recognition by Enzyme-Linked Immunospot (ELISPOT)",
            "SecondaryOutcomeDescription": "Assays of peptide pool sets covering the Gag, Env or Pol will be evaluated by standard enzyme-linked immunospot assay (ELISPOT) with mapping of positive pools to determine the number of positive epitopes.",
            "SecondaryOutcomeTimeFrame": "Week 96"
          },
          {
            "SecondaryOutcomeMeasure": "Breadth of Epitope Recognition by Enzyme-Linked Immunospot (ELISPOT)",
            "SecondaryOutcomeDescription": "Assays of peptide pool sets covering the Gag, Env or Pol will be evaluated by standard enzyme-linked immunospot assay (ELISPOT) with mapping of positive pools to determine the number of positive epitopes.",
            "SecondaryOutcomeTimeFrame": "Week 96"
          },
          {
            "SecondaryOutcomeMeasure": "Polyfunctionality of Thymus (T) cell Responses",
            "SecondaryOutcomeDescription": "Polyfunctionality of T cell responses allow correlations to reveal the critical information on therapeutic vaccination and treatment interruption and evaluation of immunogenicity.",
            "SecondaryOutcomeTimeFrame": "Week 96"
          },
          {
            "SecondaryOutcomeMeasure": "Number of Binding Antibody to Envelope (Env) Regions",
            "SecondaryOutcomeDescription": "Binding antibody to immunogen inserts and a panel of HIV envelope proteins representing the circulating HIV-1 strains will assess the immunogenicity.",
            "SecondaryOutcomeTimeFrame": "Week 96"
          },
          {
            "SecondaryOutcomeMeasure": "Breadth of antibody neutralization across different HIV-1 strains from different clades will assess immunogenicity as measured in the TZM-bl neutralization assay",
            "SecondaryOutcomeDescription": "Inducing potent neutralizing antibodies (that are group specific and capable of neutralizing all isolates of HIV-1) will evaluate the immunogenicity.",
            "SecondaryOutcomeTimeFrame": "Week 96"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nConfirmed human immunodeficiency virus (HIV)-1 infected and started antiretroviral therapy (ART) during acute infection (Fiebig stages I, II, III or IV) as part of trial RV254\nTreatment with current stable antiretroviral therapy (ART) (no changes to treatment) for at least 4 weeks prior to screening\nAll female participants of childbearing potential must have a negative serum pregnancy test (beta human chorionic gonadotropin) at the screening visit, and a negative urine pregnancy test prior to vaccination on Day 1 and prior to subsequent study vaccinations\nHIV ribonucleic acid (RNA) less than (<)50 copies per milliliter (copies/ml) for at least 48 weeks at screening: a) One blip of HIV RNA greater than (>)50 and <200 copies/ml within 48 weeks is acceptable, provided that the most recent (before screening) HIV RNA <50 copies/ml\nLaboratory criteria during screening: a) Hemoglobin: Women: greater than or equal to >=11 gram/deciliter (g/dL); Men >=12.5 g/dL, b) White cell count: 2,500 to 11,000 cells per cubic millimeter (cells/mm^3), c) Platelets: 125,000 to 450,000 per mm^3, d) Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) less than or equal to <=1.5x institutional upper limits of normal (ULN), e) Creatinine <=1.5x institutional ULN, f) CD4 > 400 cells/mm^3, g) Troponin <1x ULN\nA woman must be either: a) Not of childbearing potential: postmenopausal (>45 years of age with amenorrhea for at least 2 years, or any age with amenorrhea for at least 6 months and a serum follicle stimulation hormone [FSH] level >40 International Units Per Liter (IU/L); surgically sterile; or b) Of child-bearing potential and practicing an effective double method of birth control (example, prescription oral contraceptives, contraceptive injections, intrauterine device, contraceptive patch, or vaginal ring, in conjunction with either a female condom or one of the methods for male contraception before entry and through 3 months after the last vaccination\n\nExclusion Criteria:\n\nReceipt of any vaccine within 30 days prior to the first vaccination or plans to receive within 30 days post-vaccination. In the case of medically indicated vaccines, the vaccination should be given at least 2 weeks before or after the first vaccination. However, if a vaccine is indicated in a post exposure setting (example, rabies or tetanus), it must take priority over the study vaccine and same rules will apply to subsequent study vaccinations\nAny history of HIV-related illness under Centers for Disease Control and Prevention (CDC) category C\nHistory of myocarditis, pericarditis, cardiomyopathy, congestive heart failure with permanent sequelae, clinically significant arrhythmia (including any arrhythmia requiring medication, treatment, or clinical follow-up)\nChronic active hepatitis B or active hepatitis C (for example, positive serology with confirmatory positive polymerase chain reaction) or active syphilis infection. Active syphilis documented by examination or serology unless positive serology is due to past treated infection\nReceipt of blood products or immunoglobulin in the past 3 months\nHistory of anaphylaxis or other serious adverse reactions to vaccines or vaccine products, or neomycin or streptomycin or egg products\nHistory of chronic urticaria (recurrent hives)\nChronic or recurrent use of medications which modify host immune response, example (e.g.) cancer chemotherapeutic agents, parenteral corticosteroids (short course oral steroids given for non-chronic conditions not expected to recur is not an exclusion criteria, topical steroid use is not an exclusion criteria), etc. but not including ART",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "18 Years",
      "MaximumAge": "50 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "Janssen Vaccines & Prevention B.V. Clinical Trial",
            "OverallOfficialAffiliation": "Janssen Vaccines & Prevention B.V.",
            "OverallOfficialRole": "Study Director"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationCity": "Bangkok",
            "LocationCountry": "Thailand"
          }
        ]
      }
    },
    "ReferencesModule": {
      "ReferenceList": {
        "Reference": [
          {
            "ReferencePMID": "32235883",
            "ReferenceType": "derived",
            "ReferenceCitation": "Colby DJ, Sarnecki M, Barouch DH, Tipsuk S, Stieh DJ, Kroon E, Schuetz A, Intasan J, Sacdalan C, Pinyakorn S, Grandin P, Song H, Tovanabutra S, Shubin Z, Kim D, Paquin-Proulx D, Eller MA, Thomas R, de Souza M, Wieczorek L, Polonis VR, Pagliuzza A, Chomont N, Peter L, Nkolola JP, Vingerhoets J, Truyers C, Pau MG, Schuitemaker H, Phanuphak N, Michael N, Robb ML, Tomaka FL, Ananworanich J. Safety and immunogenicity of Ad26 and MVA vaccines in acutely treated HIV and effect on viral rebound after antiretroviral therapy interruption. Nat Med. 2020 Apr;26(4):498-501. doi: 10.1038/s41591-020-0774-y. Epub 2020 Mar 23."
          }
        ]
      }
    }
  },
  "ResultsSection": {
    "MoreInfoModule": {}
  },
  "AnnotationSection": {
    "AnnotationModule": {
      "UnpostedAnnotation": {
        "UnpostedResponsibleParty": "Janssen Vaccines & Prevention B.V.",
        "UnpostedEventList": {
          "UnpostedEvent": [
            {
              "UnpostedEventType": "Release",
              "UnpostedEventDate": "September 17, 2021"
            },
            {
              "UnpostedEventType": "Reset",
              "UnpostedEventDate": "October 15, 2021"
            },
            {
              "UnpostedEventType": "Release",
              "UnpostedEventDate": "November 9, 2021"
            },
            {
              "UnpostedEventType": "Reset",
              "UnpostedEventDate": "December 7, 2021"
            }
          ]
        }
      }
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000000163",
            "ConditionMeshTerm": "Acquired Immunodeficiency Syndrome"
          },
          {
            "ConditionMeshId": "D000015658",
            "ConditionMeshTerm": "HIV Infections"
          },
          {
            "ConditionMeshId": "D000007153",
            "ConditionMeshTerm": "Immunologic Deficiency Syndromes"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000007154",
            "ConditionAncestorTerm": "Immune System Diseases"
          },
          {
            "ConditionAncestorId": "D000086982",
            "ConditionAncestorTerm": "Blood-Borne Infections"
          },
          {
            "ConditionAncestorId": "D000003141",
            "ConditionAncestorTerm": "Communicable Diseases"
          },
          {
            "ConditionAncestorId": "D000007239",
            "ConditionAncestorTerm": "Infections"
          },
          {
            "ConditionAncestorId": "D000015229",
            "ConditionAncestorTerm": "Sexually Transmitted Diseases, Viral"
          },
          {
            "ConditionAncestorId": "D000012749",
            "ConditionAncestorTerm": "Sexually Transmitted Diseases"
          },
          {
            "ConditionAncestorId": "D000016180",
            "ConditionAncestorTerm": "Lentivirus Infections"
          },
          {
            "ConditionAncestorId": "D000012192",
            "ConditionAncestorTerm": "Retroviridae Infections"
          },
          {
            "ConditionAncestorId": "D000012327",
            "ConditionAncestorTerm": "RNA Virus Infections"
          },
          {
            "ConditionAncestorId": "D000014777",
            "ConditionAncestorTerm": "Virus Diseases"
          },
          {
            "ConditionAncestorId": "D000012897",
            "ConditionAncestorTerm": "Slow Virus Diseases"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M17402",
            "ConditionBrowseLeafName": "HIV Infections",
            "ConditionBrowseLeafAsFound": "Human Immunodeficiency Virus",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M9435",
            "ConditionBrowseLeafName": "Infections",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M5520",
            "ConditionBrowseLeafName": "Communicable Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M16674",
            "ConditionBrowseLeafName": "Virus Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M2674",
            "ConditionBrowseLeafName": "Acquired Immunodeficiency Syndrome",
            "ConditionBrowseLeafAsFound": "Human Immunodeficiency Virus",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M9351",
            "ConditionBrowseLeafName": "Immunologic Deficiency Syndromes",
            "ConditionBrowseLeafAsFound": "Immunodeficiency",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M2762",
            "ConditionBrowseLeafName": "Adenoviridae Infections",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M16515",
            "ConditionBrowseLeafName": "Vaccinia",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M15507",
            "ConditionBrowseLeafName": "Syndrome",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M9352",
            "ConditionBrowseLeafName": "Immune System Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M14710",
            "ConditionBrowseLeafName": "Sexually Transmitted Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M17085",
            "ConditionBrowseLeafName": "Sexually Transmitted Diseases, Viral",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M17792",
            "ConditionBrowseLeafName": "Lentivirus Infections",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M14178",
            "ConditionBrowseLeafName": "Retroviridae Infections",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M14301",
            "ConditionBrowseLeafName": "RNA Virus Infections",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M14852",
            "ConditionBrowseLeafName": "Slow Virus Diseases",
            "ConditionBrowseLeafRelevance": "low"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC01",
            "ConditionBrowseBranchName": "Infections"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC20",
            "ConditionBrowseBranchName": "Immune System Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC23",
            "ConditionBrowseBranchName": "Symptoms and General Pathology"
          },
          {
            "ConditionBrowseBranchAbbrev": "BXS",
            "ConditionBrowseBranchName": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
          }
        ]
      }
    },
    "InterventionBrowseModule": {
      "InterventionBrowseLeafList": {
        "InterventionBrowseLeaf": [
          {
            "InterventionBrowseLeafId": "M16512",
            "InterventionBrowseLeafName": "Vaccines",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M24581",
            "InterventionBrowseLeafName": "Anti-Retroviral Agents",
            "InterventionBrowseLeafRelevance": "low"
          }
        ]
      },
      "InterventionBrowseBranchList": {
        "InterventionBrowseBranch": [
          {
            "InterventionBrowseBranchAbbrev": "All",
            "InterventionBrowseBranchName": "All Drugs and Chemicals"
          },
          {
            "InterventionBrowseBranchAbbrev": "Infe",
            "InterventionBrowseBranchName": "Anti-Infective Agents"
          }
        ]
      }
    }
  }
}